{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:14:16Z","timestamp":1759331656926,"version":"build-2065373602"},"reference-count":74,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.arcmed.2020.09.001","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T17:26:08Z","timestamp":1600104368000},"page":"817-826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular Oncology of Gynecologic Tumors"],"prefix":"10.1016","volume":"51","author":[{"given":"Isabel","family":"Alvarado-Cabrero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2020.09.001_bib2","first-page":"7","article-title":"Cancer statistics, 2019","volume":"6","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.arcmed.2020.09.001_bib3","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.2217\/fon.14.192","article-title":"USA endometrial cancer projections to 2030: should we be concerned?","volume":"10","author":"Sheikh","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib4","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1001\/jamainternmed.2018.2819","article-title":"Opportunities for Early Detection of Endometrial Cancer in Women with Postmenopausal Bleeding","volume":"178","author":"Matteson","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.arcmed.2020.09.001_bib5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2174\/1568009614666140506111118","article-title":"Prognostic and Predictive Biomarkers in Cancer","volume":"14","author":"Nair","year":"2014","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.arcmed.2020.09.001_bib6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/0284186X.2018.1540886","article-title":"The role of biomarkers in endometrial cancer and hyperplasia: a literature review","volume":"58","author":"Hutt","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/path.4056","article-title":"Use of mutation profiles to refine the classification of endometrial carcinomas","volume":"228","author":"McConechy","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib8","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00404-019-05123-x","article-title":"PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis","volume":"299","author":"Raffone","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.arcmed.2020.09.001_bib9","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.0.CO;2-U","article-title":"The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways","volume":"88","author":"Lax","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.arcmed.2020.09.001_bib10","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1002\/cncr.10498","article-title":"Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis","volume":"94","author":"Koul","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.arcmed.2020.09.001_bib11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/modpathol.2012.174","article-title":"ARID1A loss is prevalent in endometrial hyperplasia and low-grade endometrioid carcinomas","volume":"26","author":"Werner","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib12","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1002\/jcp.24016","article-title":"New insights in endometrial carcinogenesis","volume":"227","author":"D\u2019Andrilli","year":"2012","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00004347-200404000-00007","article-title":"Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level","volume":"23","author":"Alkushi","year":"2004","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib14","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility","volume":"38","author":"K\u00f6bel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib15","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/mc.20850","article-title":"PPP2RIA mutations are common in the serous type of endometrial cancer","volume":"51","author":"Nagendra","year":"2012","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.arcmed.2020.09.001_bib16","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1097\/PAS.0000000000000321","article-title":"Lynch syndrome screening should be considering for all patients with newly diagnosed endometrial cancer","volume":"38","author":"Mills","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/107327480901600103","article-title":"Endometrial Cancer and Lynch Syndrome: Clinical and Pathologic Considerations","volume":"16","author":"Meyer","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.arcmed.2020.09.001_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2016.12.010","article-title":"Bokhman redux: endometrial cancer \u201ctypes\u201d in the 21st century","volume":"144","author":"Suarez","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.arcmed.2020.09.001_bib21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/his.13338","article-title":"Blinded histopathological characterization of pole exonuclease domain-mutant endometrial cancers: sheep in wolf\u2019s clothing","volume":"72","author":"Van Gool","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.arcmed.2020.09.001_bib22","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.18632\/oncotarget.23790","article-title":"Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer","volume":"9","author":"Yamashita","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.arcmed.2020.09.001_bib23","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1158\/0008-5472.CAN-06-1114","article-title":"Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients","volume":"66","author":"Hampel","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.arcmed.2020.09.001_bib24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancer","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.arcmed.2020.09.001_bib25","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.arcmed.2020.09.001_bib26","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final Validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; A TransPORTEC initiative","volume":"28","author":"Stello","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib28","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.radonc.2015.11.013","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up","volume":"117","author":"Colombo","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-019-0825-z","article-title":"Selecting Adjuvant treatment for endometrial carcinoma using molecular risk factors","volume":"21","author":"Wortman","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.arcmed.2020.09.001_bib30","first-page":"429","article-title":"Past, present, and future of hormonal therapy in recurrent endometrial cancer","volume":"6","author":"Carlson","year":"2014","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.arcmed.2020.09.001_bib31","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/IGC.0000000000001187","article-title":"Added value of estrogen receptor, progesterone receptor, and L1 cell adhesion molecule expression to histology\u2013based endometrial carcinoma recurrence prediction model: an ENITEC collaboration study","volume":"28","author":"van der Putten","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.arcmed.2020.09.001_bib32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2007.03.042","article-title":"Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: A Gynecologic Oncology Group Study","volume":"106","author":"Singh","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/13543784.2018.1558202","article-title":"Investigational PI3K\/AKT\/mTOR inhibitors in development for endometrial cancer","volume":"28","author":"Barra","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.arcmed.2020.09.001_bib34","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/1078-0432.CCR-19-0471","article-title":"Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study","volume":"26","author":"Soliman","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2020.09.001_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.10.003","article-title":"Targeting mTOR pathway in gynecological malignancies: Biological rationale and systematic review of published data","volume":"108","author":"Kassem","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib36","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2174\/1389201020666190717092448","article-title":"Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer","volume":"20","author":"Dziobek","year":"2019","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib37","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2018.05.018","article-title":"A phase II study of frontline\u00a0paclitaxel\/carboplatin\/bevacizumab, paclitaxel\/carboplatin\/temsirolimus, or ixabepilone\/carboplatin\/bevacizumab in advanced\/recurrent endometrial cancer","volume":"150","author":"Aghajanian","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib38","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ygyno.2019.10.013","article-title":"Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial","volume":"155","author":"Lorusso","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib39","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib40","doi-asserted-by":"crossref","first-page":"90532","DOI":"10.18632\/oncotarget.20042","article-title":"Checkpoints inhibitors in endometrial cancer: preclinical rationales and clinical activity","volume":"8","author":"Mittica","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.arcmed.2020.09.001_bib41","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2020.09.001_bib43","first-page":"7","article-title":"Cancer statics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.arcmed.2020.09.001_bib44","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00404-019-05269-8","article-title":"Socioeconomic differences impact overall survival in advanced ovarian cancer prior to achievement of standard therapy","volume":"300","author":"Phillips","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.arcmed.2020.09.001_bib45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","article-title":"The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin","volume":"23","author":"Seidman","year":"2004","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib46","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","article-title":"Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features","volume":"460","author":"Prat","year":"2012","journal-title":"Virchows Arch"},{"key":"10.1016\/j.arcmed.2020.09.001_bib47","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","article-title":"Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biological features, and diagnostic problems","volume":"16","author":"Vang","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib48","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.arcmed.2020.09.001_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/pgp.0b013e31814b191f","article-title":"Serous carcinogenesis in the fallopian tube: a descriptive classification","volume":"27","author":"Jarboe","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib50","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib51","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.arcmed.2020.09.001_bib52","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA-1 and BRCA-2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00096","article-title":"Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma","volume":"3","author":"Shilpi","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.arcmed.2020.09.001_bib54","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1158\/1078-0432.CCR-18-0784","article-title":"Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2020.09.001_bib55","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2012.04.021","article-title":"Clear cell carcinoma of the ovary: a review of the literature","volume":"126","author":"Del Carmen","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib56","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1126\/science.1196333","article-title":"Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma","volume":"330","author":"Jones","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.arcmed.2020.09.001_bib57","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ygyno.2017.09.027","article-title":"Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer","volume":"147","author":"Matsuo","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib58","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.path.2019.01.009","article-title":"Pathology of Endometrioid and Clear Cell Carcinoma of the Ovary","volume":"12","author":"Fadare","year":"2019","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.arcmed.2020.09.001_bib59","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2020.09.001_bib60","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ygyno.2019.07.012","article-title":"Molecular profiling and molecular classification of endometrioid ovarian carcinomas","volume":"154","author":"Cybulska","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.12.002","article-title":"PARP inhibitors in ovarian cancer","volume":"73","author":"Franzese","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.arcmed.2020.09.001_bib63","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2174\/1574892813666180305165256","article-title":"PARP Inhibitors in Ovarian Cancer","volume":"13","author":"Mittica","year":"2018","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1016\/j.arcmed.2020.09.001_bib64","first-page":"348","article-title":"Angiogenesis in epithelial ovarian cancer","volume":"55","author":"Bamberger","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib65","doi-asserted-by":"crossref","first-page":"12389","DOI":"10.18632\/oncotarget.13310","article-title":"Bevacizumab in ovarian cancer: A critical review of phase III studies","volume":"8","author":"Rossi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.arcmed.2020.09.001_bib66","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2020.09.001_bib67","doi-asserted-by":"crossref","first-page":"e1032476","DOI":"10.1080\/23723556.2015.1032476","article-title":"Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations","volume":"3","author":"Bitler","year":"2015","journal-title":"Mol Cell Oncol"},{"year":"2018","series-title":"Global Cancer Observatory: cancer today","author":"Ferlay","key":"10.1016\/j.arcmed.2020.09.001_bib68"},{"key":"10.1016\/j.arcmed.2020.09.001_bib69","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancer in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.arcmed.2020.09.001_bib70","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature21386","article-title":"Analytical Biological Services, et\u00a0al. Integrated genomic and molecular characterization of cervical cancer","volume":"543","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.arcmed.2020.09.001_bib71","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.csbj.2019.02.001","article-title":"Recent advances on the molecular mechanism of cervical carcinogenesis based on systems biology technologies","volume":"17","author":"Lin","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.arcmed.2020.09.001_bib72","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/PGP.0000000000000121","article-title":"Dysregulation of CDK Inhibitors and p53 in HPV-negative Endocervical Adenocarcinoma","volume":"34","author":"Omori","year":"2015","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib73","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2020.09.001_bib74","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3892\/mmr.2017.6102","article-title":"Increased expression of PDL1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity","volume":"15","author":"Liu","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.arcmed.2020.09.001_bib75","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2015.108","article-title":"Enhanced expression of PDL1 in cervical intraepithelial neoplasia and cervical cancers","volume":"28","author":"Mezache","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.arcmed.2020.09.001_bib76","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/1758834017708742","article-title":"Pembrolizumab in cervical cancer: latest evidence and clinical usefulness","volume":"9","author":"Borcoman","year":"2017","journal-title":"Ther Adv Med Oncol"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440920312625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440920312625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:49:41Z","timestamp":1759261781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440920312625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0188440920312625"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2020.09.001","relation":{},"ISSN":["0188-4409"],"issn-type":[{"type":"print","value":"0188-4409"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Oncology of Gynecologic Tumors","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2020.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 IMSS. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}